Rituximab's cost for the treatment of primary cold agglutinin disease should not limit its use
| Autor: | Delluc, Aurelien, Pasquier, Elisabeth, De Saint Martin, Luc, Mottier, Dominique |
|---|---|
| Přispěvatelé: | Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Calvez, Ghislaine |
| Jazyk: | angličtina |
| Rok vydání: | 2006 |
| Předmět: |
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology
MESH: Humans Cost-Benefit Analysis Antibodies Monoclonal MESH: Antibodies Monoclonal Antibodies Monoclonal Murine-Derived MESH: Antibodies Monoclonal Murine-Derived Humans Anemia Hemolytic Autoimmune MESH: Anemia Hemolytic Autoimmune Rituximab ComputingMilieux_MISCELLANEOUS [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology MESH: Cost-Benefit Analysis |
| Zdroj: | Haematologica Haematologica, Ferrata Storti Foundation, 2006, 91 (3), pp.ECR05 |
| ISSN: | 0390-6078 1592-8721 |
| Popis: | International audience |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|